BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 17101698)

  • 1. Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration.
    Nishita M; Yoo SK; Nomachi A; Kani S; Sougawa N; Ohta Y; Takada S; Kikuchi A; Minami Y
    J Cell Biol; 2006 Nov; 175(4):555-62. PubMed ID: 17101698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A.
    Nomachi A; Nishita M; Inaba D; Enomoto M; Hamasaki M; Minami Y
    J Biol Chem; 2008 Oct; 283(41):27973-27981. PubMed ID: 18667433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2.
    Yamamoto H; Yoo SK; Nishita M; Kikuchi A; Minami Y
    Genes Cells; 2007 Nov; 12(11):1215-23. PubMed ID: 17986005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ror2/Frizzled complex mediates Wnt5a-induced AP-1 activation by regulating Dishevelled polymerization.
    Nishita M; Itsukushima S; Nomachi A; Endo M; Wang Z; Inaba D; Qiao S; Takada S; Kikuchi A; Minami Y
    Mol Cell Biol; 2010 Jul; 30(14):3610-9. PubMed ID: 20457807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase.
    Liu Y; Rubin B; Bodine PV; Billiard J
    J Cell Biochem; 2008 Oct; 105(2):497-502. PubMed ID: 18615587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells.
    Yuan Y; Niu CC; Deng G; Li ZQ; Pan J; Zhao C; Yang ZL; Si WK
    Int J Mol Med; 2011 Jan; 27(1):63-9. PubMed ID: 21069266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative regulation of Wnt signaling mediated by CK1-phosphorylated Dishevelled via Ror2.
    Witte F; Bernatik O; Kirchner K; Masek J; Mahl A; Krejci P; Mundlos S; Schambony A; Bryja V; Stricker S
    FASEB J; 2010 Jul; 24(7):2417-26. PubMed ID: 20215527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases.
    Minami Y; Oishi I; Endo M; Nishita M
    Dev Dyn; 2010 Jan; 239(1):1-15. PubMed ID: 19530173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway.
    Oishi I; Suzuki H; Onishi N; Takada R; Kani S; Ohkawara B; Koshida I; Suzuki K; Yamada G; Schwabe GC; Mundlos S; Shibuya H; Takada S; Minami Y
    Genes Cells; 2003 Jul; 8(7):645-54. PubMed ID: 12839624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context.
    Mikels AJ; Nusse R
    PLoS Biol; 2006 Apr; 4(4):e115. PubMed ID: 16602827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression.
    Yamagata K; Li X; Ikegaki S; Oneyama C; Okada M; Nishita M; Minami Y
    J Biol Chem; 2012 Jan; 287(2):1588-99. PubMed ID: 22128168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.
    Enomoto M; Hayakawa S; Itsukushima S; Ren DY; Matsuo M; Tamada K; Oneyama C; Okada M; Takumi T; Nishita M; Minami Y
    Oncogene; 2009 Sep; 28(36):3197-208. PubMed ID: 19561643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt5A activates the calpain-mediated cleavage of filamin A.
    O'Connell MP; Fiori JL; Baugher KM; Indig FE; French AD; Camilli TC; Frank BP; Earley R; Hoek KS; Hasskamp JH; Elias EG; Taub DD; Bernier M; Weeraratna AT
    J Invest Dermatol; 2009 Jul; 129(7):1782-9. PubMed ID: 19177143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
    Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
    J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt-ligand-dependent interaction of TAK1 (TGF-beta-activated kinase-1) with the receptor tyrosine kinase Ror2 modulates canonical Wnt-signalling.
    Winkel A; Stricker S; Tylzanowski P; Seiffart V; Mundlos S; Gross G; Hoffmann A
    Cell Signal; 2008 Nov; 20(11):2134-44. PubMed ID: 18762249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the role of Wnt5a-induced signaling in normal and cancer cells.
    Endo M; Nishita M; Fujii M; Minami Y
    Int Rev Cell Mol Biol; 2015; 314():117-48. PubMed ID: 25619716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Meckel-Gruber syndrome protein TMEM67 controls basal body positioning and epithelial branching morphogenesis in mice via the non-canonical Wnt pathway.
    Abdelhamed ZA; Natarajan S; Wheway G; Inglehearn CF; Toomes C; Johnson CA; Jagger DJ
    Dis Model Mech; 2015 Jun; 8(6):527-41. PubMed ID: 26035863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wnt5a regulates directional cell migration and cell proliferation via Ror2-mediated noncanonical pathway in mammalian palate development.
    He F; Xiong W; Yu X; Espinoza-Lewis R; Liu C; Gu S; Nishita M; Suzuki K; Yamada G; Minami Y; Chen Y
    Development; 2008 Dec; 135(23):3871-9. PubMed ID: 18948417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE.
    Lai SS; Xue B; Yang Y; Zhao L; Chu CS; Hao JY; Wen CJ
    Cancer Genet; 2012 Nov; 205(11):552-62. PubMed ID: 23142633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
    Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
    Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.